Sex-Associated Differences in the Antibody-Dependent Cellular Cytotoxicity Antibody Response to Measles Vaccines
Open Access
- 1 January 2000
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Diagnostic Laboratory Immunology
- Vol. 7 (1) , 31-39
- https://doi.org/10.1128/cdli.7.1.111-113.2000
Abstract
Certain bacteria, including overt pathogens as well as commensals, produce immunoglobulin A1 (IgA1) proteases. By cleaving IgA1, including secretory IgA1, in the hinge region, these enzymes may interfere with the barrier functions of mucosal IgA antibodies, as indicated by experiments in vitro. Previous studies have suggested that cleavage of IgA1 in nasal secretions may be associated with the development and perpetuation of atopic disease. To clarify the potential effect of IgA1 protease-producing bacteria in the nasal cavity, we have analyzed immunoglobulin isotypes in nasal secretions of 11 healthy humans, with a focus on IgA, and at the same time have characterized and quantified IgA1 protease-producing bacteria in the nasal flora of the subjects. Samples in the form of nasal wash were collected by using a washing liquid that contained lithium as an internal reference. Dilution factors and, subsequently, concentrations in undiluted secretions could thereby be calculated. IgA, mainly in the secretory form, was found by enzyme-linked immunosorbent assay to be the dominant isotype in all subjects, and the vast majority of IgA (median, 91%) was of the A1 subclass, corroborating results of previous analyses at the level of immunoglobulin-producing cells. Levels of serum-type immunoglobulins were low, except for four subjects in whom levels of IgG corresponded to 20 to 66% of total IgA. Cumulative levels of IgA, IgG, and IgM in undiluted secretions ranged from 260 to 2,494 (median, 777) μg ml−1. IgA1 protease-producing bacteria (Haemophilus influenzae, Streptococcus pneumoniae, orStreptococcus mitis biovar 1) were isolated from the nasal cavities of seven subjects at 2.1 × 103 to 7.2 × 106 CFU per ml of undiluted secretion, corresponding to 0.2 to 99.6% of the flora. Nevertheless, α-chain fragments characteristic of IgA1 protease activity were not detected in secretions from any subject by immunoblotting. Neutralizing antibodies to IgA1 proteases of autologous isolates were detected in secretions from five of the seven subjects but not in those from two subjects harboring IgA1 protease-producing S. mitis biovar 1. α-chain fragments different from Fcα and Fdα were detected in some samples, possibly reflecting nonspecific proteolytic activity of microbial or host origin. These results add to previous evidence for a role of secretory immunity in the defense of the nasal mucosa but do not help identify conditions under which bacterial IgA1 proteases may interfere with this defense.Keywords
This publication has 17 references indexed in Scilit:
- The Effect of Edmonston-Zagreb and Schwarz Measles Vaccines on Immune Responses in InfantsThe Journal of Infectious Diseases, 1996
- Age, Sex, and Household Exposure Are Associated with the Acute Measles-Specific Antibody-Dependent Cellular Cytotoxicity Antibody ResponseThe Journal of Infectious Diseases, 1995
- Sex Differences in Measles Mortality: A World ReviewInternational Journal of Epidemiology, 1994
- Long term impact of high titer Edmonston-Zagreb measles vaccine on T lymphocyte subsetsThe Pediatric Infectious Disease Journal, 1994
- Immunologic Parameters 2 Years after High-Titer Measles Immunization in Peruvian ChildreThe Journal of Infectious Diseases, 1993
- Differential Mortality by Measles Vaccine Titer and SexThe Journal of Infectious Diseases, 1993
- Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: Increased female mortality rateThe Journal of Pediatrics, 1993
- Antibody persistence in Gambian children after high-dose Edmonston-Zagreb measles vaccineThe Lancet, 1990
- Pattern of Exposure and Measles Mortality in SenegalThe Journal of Infectious Diseases, 1990
- TRIAL OF HIGH-DOSE EDMONSTON-ZAGREB MEASLES VACCINE IN THE GAMBIA: ANTIBODY RESPONSE AND SIDE-EFFECTSThe Lancet, 1988